Cognivue

Cognivue®’s FDA-cleared technology digitally assesses cognitive functioning.

We strive to deliver on our mission to provide cognitive assessment tools to a broad range of healthcare providers for the early detection of cognitive changes.

01/14/2026

Now live: Cognivue’s Education Page for HCP education.

We’re excited to make it easier to browse a growing set of on-demand webinars and clinical learning resources in one place. More additions to come.

Visit the learning library: https://bit.ly/49CSO5I

01/08/2026

Did you know nearly half of dementia cases may be preventable?

The 2024 Lancet Commission reports that 45% of dementia cases are potentially preventable by addressing 14 modifiable risk factors, many of which develop across early life, midlife, and later years. [1]

Cognivue is committed to supporting brain health with tools that help identify cognitive changes earlier. That is why proactive brain health matters, and why early cognitive screening can be an important step in identifying changes sooner, when intervention, planning, and support may have the greatest impact.

Let’s keep building awareness around prevention, risk reduction, and earlier insight.

Reference:
[1] Livingston G, Huntley J, Liu K, et al. (2024). Dementia Prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 404(10452), 572–628. DOI: 10.1016/S0140-6736(24)01296-0.

12/30/2025

As 2025 comes to a close, we reflect on a year defined by our continued commitment to advancing cognitive health.

At the heart of this work is a belief that earlier, richer cognitive insight can support more informed conversations, more personalized patient care, and clearer pathways for clinical decisions. Education plays an important role in shaping how cognitive health is understood and addressed across care settings.

Looking ahead to 2026, Cognivue remains focused on expanding awareness, continuing validation efforts and clinician education, and supporting those dedicated to improving cognitive health across diverse populations.

As shared by Cognivue's President & CEO, Paul W. Estes, “Advancing how cognitive performance is measured requires a commitment to education, evidence, and collaboration. In 2025, we made important strides in supporting earlier cognitive insight, and in 2026, we will continue building pathways that help clinicians and researchers better serve patients and communities.”

We are grateful to our partners, collaborators, and team members who contributed to this journey. We enter the new year with focus, optimism, and purpose.

12/23/2025

Maintain Connections ( )! Studies have shown that increased social activity is linked to a lower rate of cognitive decline [1]. To stay social, connect with friends and family, or consider volunteering for a local organization.

Reference: 1. James BD, Wilson RS, Barnes LL, Bennett DA. Late-life social activity and cognitive decline in old age. J Int Neuropsychol Soc. 2011 Nov;17(6):998-1005.

12/18/2025

Why does adaptive psychophysics matter in cognitive assessment?

As Dr. James E. Galvin, MD, MPH, explains in the clip below, adaptive psychophysics helps the assessment calibrate to the person taking it—setting an individual baseline and using that person as their own control. That allows the test to adjust for motor and visual differences and better isolate cognitive performance.

By keeping testing within an individual’s performance threshold, adaptive psychophysics can help reduce bias from physical or sensory limitations and support a more accurate measurement of cognitive performance.

This methodology is foundational to how Cognivue devices generate objective cognitive performance data tailored to each patient.

12/12/2025

Happy ! Today we’re celebrating the incredible people who bring Cognivue's mission to life every day. The images in this grid reflect the spirit of many of the individuals—across the field and behind the scenes—who contribute to our shared commitment to advancing cognitive health. And when it comes to our Sales team, whether they’re on the road, in clinics, supporting practices, or championing cognitive health, each person plays a vital role in bringing meaningful change to both patients and providers.

We’re also proud to celebrate a milestone this year: being named the “Top Cognitive Impairment Early Detection Company of 2025” by Healthcare Tech Outlook. This recognition reflects the hard work of our whole organization, and our sales team is a vital part of that success. Their dedication to partnering with healthcare providers, supporting clinical workflows, and expanding access to cognitive screening continues to drive our momentum and amplify the impact we’re making nationwide.

To our sales professionals: thank you for showing up with heart, resilience, and purpose. Your work strengthens our mission and helps more clinicians bring cognitive health into everyday care. Today, we honor you—and we’re excited for everything we’ll achieve together.

12/10/2025

🧠 Pleased to share our CTAD 2025 poster!
We presented findings on how a two-stage screening strategy using a digital cognitive biomarker (Cognivue Clarity) followed by a blood-based biomarker (LucentAD Complete) helps classify individuals for clinical trial recruitment enrichment and treatment protocols.

🔍 Key findings:
Using the Bio-Hermes study sample, we tested this two-stage approach to mimic how individuals might be evaluated in clinical practice. This strategy classified 85% of individuals into meaningful groups—those likely to have Alzheimer’s disease versus those who do not—leaving only 15% who would require a confirmatory amyloid PET scan.

This cost-effective approach could increase the likelihood of identifying early AD for treatment or trial enrollment, while reducing reliance on costly PET imaging and improving sample enrichment in low-prevalence settings.

Proud to collaborate with Lucent Diagnostics on this important work.

📄 View Poster: https://bit.ly/48SMtUt

12/04/2025

🧠 Live from CTAD 2025!
Great to share our collaborative poster with Lucent Diagnostics, showcasing how a two-stage screening strategy—digital cognitive biomarker + blood-based biomarker—can help drive more efficient Alzheimer’s clinical trial recruitment and support treatment protocols.

It was wonderful having four of the six poster authors on-site and engaging with the scientific community: James E. Galvin, Lindsey Mette, Dave Wilson, and Heather M. Harris.

📸 A few moments from the poster session below!

Cognivue

12/01/2025

👉 Cognivue + Lucent Diagnostics at CTAD 2025!

We’re excited to share that Cognivue and Lucent Diagnostics will be featured together in a poster presentation at the Clinical Trials on Alzheimer’s Disease (CTAD Conference)—highlighting how a digital cognitive biomarker and a blood-based biomarker can be paired in a two-stage screening approach to support more efficient Alzheimer’s clinical trial recruitment.

Poster Details:
📌 Poster | 📍 Indigo Ballroom – Level 2
📅 Wednesday, December 3 | 🕢 7:15 AM – 5:30 PM

Poster Title:
“Combining Cognivue Clarity and Lucent AD Complete for a Time and Cost Efficient Two Stage Screening for Alzheimer's Disease Clinical Trial Recruitment Enrichment and Treatment Protocols”

Heading to CTAD? Stop by Poster and view the full findings!

11/24/2025

One of the most powerful aspects of Cognivue’s technology is its use of adaptive psychophysics—a science-driven method that personalizes each assessment in real time.

In our recent webinar, “Measuring What Matters: Integrating Cognitive Assessment into Geriatric Care Pathways,” Dr. Ardeshir Z. Hashmi of the Cleveland Clinic explained it best. In the clip below, he describes how an adaptive test should work:

➡️ If a patient answers correctly, the system increases difficulty—one step at a time.
➡️ When they reach their limit, it confirms that threshold with similar-level tasks.
➡️ That point becomes the patient’s unique cognitive fingerprint, which can be tracked over time.

This is precisely how Cognivue technology works—adapting each assessment in real time, calibrating to a patient’s motor and visual abilities, and adjusting difficulty until it identifies their performance limits.

Watch the full webinar On Demand (link in comments).

11/19/2025

🧠 Cognivue is headed to San Diego for the 2025 Clinical Trials on Alzheimer’s Disease CTAD Conference — taking place December 1-4!

📅 Don’t miss the chance to meet with Dr. James E. Galvin, Chief Scientific Officer, and Heather M. Harris, Sr. VP of Scientific Affairs & Partnerships. Email events@cognivue.com to schedule a meeting.

📍 Catch our poster presentation!
📌 Poster | Wednesday, December 3 | 7:15 AM – 5:30 PM
🧪 “Combining Cognivue Clarity and Lucent AD Complete for a Time and Cost Efficient Two Stage Screening for Alzheimer's Disease Clinical Trial Recruitment Enrichment and Treatment Protocols”

We’re looking forward to connecting, collaborating, and contributing to advances in Alzheimer’s clinical research. See you at !

11/11/2025

🧠 Why measure cognitive function? Because what we don’t measure, we can’t manage.

Cognitive changes impact every aspect of aging—from medication safety and mobility to social engagement and care planning. Yet routine cognitive assessment remains underused in clinical practice.

On November 19, join Dr. Ardeshir Z. Hashmi (Cleveland Clinic) and Dr. Joy Siegel (Nova Southeastern University) for forward-looking discussion on advancing geriatric care through earlier, data-driven cognitive assessment and its growing role in value-based care.

📅 November 19, 2025 | 1 PM EST / 10 AM PST
👉 Register now: https://bit.ly/47MsDIQ

Cognivue

Address

7911 Rae Boulevard
Victor, NY
14564

Telephone

+15852031969

Website

https://www.cognivue.com/

Alerts

Be the first to know and let us send you an email when Cognivue posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Cognivue:

Shortcuts

Want your practice to be the top-listed Clinic in Victor?

A Path to Cognitive Health and Peace of Mind

Cognivue® is the world’s first FDA-cleared test of cognitive function. Cognivue objectively, quantitatively and reliably identifies changes in cognitive function that could be indicative of an impairment that you may optimally treat or manage. It’s personalized, consistent and reliable.